Toggle light / dark theme

Slowfast-llava: a strong training-free baseline for video large language models.

Mingze Xu, Mingfei Gao, Zhe Gan, Hong-You Chen, Zhengfeng Lai, Haiming Gang, Kai Kang, Afshin Dehghan Apple 2024 https://huggingface.co/papers/2407.

- SlowFast-LLaVA (SF-LLaVA), a training-free video large…


Join the discussion on this paper page.

A 13-year-old boy named Oran Knowlson has become the world’s first patient to test out a brain stimulation implant to treat severe epilepsy.

Knowlson was sometimes having hundreds of seizures per day before the device was fitted. His family has stated that he’s already seeing positive changes compared to his condition before implanting the device.

They called it the God particle – a particle so ’goddamn’ elusive, it took nearly 40 years and a $4.75 billion machine to detect, all in the hopes of closing one chapter in physics and opening a new one.

Yet for all its promise, it’s possible the Higgs boson might not be the window to a new age of science.

On including previously neglected corrections to data-driven models of the Higgs boson’s creation, physicists from the Polish Academy of Sciences, the Max-Planck Institute for Physics, and the RWTH Aachen University in Germany have failed to find evidence of ‘hidden’ laws lurking in the particle’s shadow.

An exciting overview of progress made by the startup Tome Biosciences towards clinical application of the PASTE technology, a way of using CRISPR and integrases (or ligases) to programmably insert very long DNA sequences into the human genome.


Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.

Several studies have indicated that interrupted epigenetic reprogramming using Yamanaka transcription factors (OSKM) can rejuvenate cells from old laboratory animals and humans. However, the potential of OSKM-induced rejuvenation in brain tissue has been less explored. Here, we aimed to restore cognitive performance in 25.3-month-old female Sprague–Dawley rats using OSKM gene therapy for 39 days. Their progress was then compared with the cognitive performance of untreated 3.5-month-old rats as well as old control rats treated with a placebo adenovector. The Barnes maze test, used to assess cognitive performance, demonstrated enhanced cognitive abilities in old rats treated with OSKM compared to old control animals. In the treated old rats, there was a noticeable trend towards improved spatial memory relative to the old controls.